Suppr超能文献

比较全身化疗联合光动力疗法与单纯光动力疗法治疗晚期肝门部胆管癌患者的长期疗效。

Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma.

机构信息

Department of Internal Medicine, Digestive Disease Centre, Konkuk University School of Medicine, Seoul, Korea.

出版信息

Gut Liver. 2014 May;8(3):318-23. doi: 10.5009/gnl.2014.8.3.318.

Abstract

BACKGROUND/AIMS: Patients with cholangiocarcinoma usually present at an advanced stage, and more than 50% of cases are not resectable at the time of diagnosis. Recently, photodynamic therapy (PDT) has been proposed as a palliative and neoadjuvant modality. We evaluated whether combination of PDT and chemotherapy is more effective than PDT alone.

METHODS

In total, 161 patients with cholangiocarcinoma diagnosed between February 1999 and September 2009 were evaluated. Sixteen patients were treated with PDT and chemotherapy (group A), and 58 were treated with PDT (group B).

RESULTS

The median survival was 538 days (95% confidence interval [CI], 475.3 to 600.7) in group A and 334 days (95% CI, 252.5 to 415.5) in group B (p=0.05). Lymph node metastasis status, serum bilirubin of pretreatment, tumor node metastasis stage, treatment method (PDT with chemotherapy vs PDT alone), time to PDT and the number of PDT sessions were prognostic factors with statistical significance in the univariate analysis. A multivariate analysis showed that PDT with chemotherapy and more than two sessions of PDT were significant independent predictors of longer survival in advanced cholangiocarcinoma (hazard ratio [HR], 2.23; 95% CI, 1.18 to 4.20; p=0.013 vs HR, 1.79; 95% CI, 1.044 to 3.083; p=0.034).

CONCLUSIONS

PDT with chemotherapy results in longer survival than PDT alone.

摘要

背景/目的:胆管癌患者通常在晚期就诊,超过 50%的病例在诊断时无法切除。最近,光动力疗法(PDT)已被提议作为一种姑息性和新辅助治疗方法。我们评估了 PDT 联合化疗是否比单独 PDT 更有效。

方法

总共评估了 1999 年 2 月至 2009 年 9 月期间诊断的 161 例胆管癌患者。16 例患者接受 PDT 和化疗(A 组),58 例患者接受 PDT(B 组)。

结果

A 组的中位生存期为 538 天(95%置信区间 [CI],475.3 至 600.7),B 组为 334 天(95%CI,252.5 至 415.5)(p=0.05)。淋巴结转移状态、治疗前血清胆红素、肿瘤淋巴结转移分期、治疗方法(PDT 联合化疗与 PDT 单独治疗)、PDT 时间和 PDT 次数是单因素分析中具有统计学意义的预后因素。多因素分析显示,PDT 联合化疗和超过两次 PDT 是晚期胆管癌生存时间延长的独立预测因素(危险比 [HR],2.23;95%CI,1.18 至 4.20;p=0.013 与 HR,1.79;95%CI,1.044 至 3.083;p=0.034)。

结论

PDT 联合化疗比单独 PDT 可获得更长的生存期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/236c/4026651/08a63b17da69/gnl-8-318-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验